evipedia.ai
← Back

Luteolin for Health & Longevity

Evidence Review created on 09/13/2026 using AI4L / Opus 5

Also known as: 3’,4’,5,7-tetrahydroxyflavone, Luteolol, Digitoflavone, Flacitran, Luteoline

Motivation

Luteolin is a yellow plant pigment found in celery, parsley, thyme, chamomile, sweet peppers and artichoke, and sold as a concentrated capsule made from herbs or from Japanese pagoda tree buds. It belongs to the same broad family of plant compounds as quercetin. Interest in it rests mainly on one property: it quiets the immune cells that drive low-grade, long-running inflammation, including the cells that release histamine and the immune cells that live inside the brain.

Herbs rich in luteolin have been used in traditional medicine for centuries, but the compound itself entered the longevity conversation only recently, after animal work tied it to slower build-up of worn-out cells that no longer divide. Separately, dietary surveys have linked higher luteolin intake to better long-term survival, and a few supplement trials have been run in people. How little of an oral dose reaches the bloodstream has long limited what could be tested, and newer formulations aim to change that.

This review examines how luteolin acts, what the human and animal evidence shows for benefit and for harm, how it is dosed, sourced and monitored, and how the laboratory findings compare with what has been tested in people.

Benefits - Risks - Protocol - Conclusion

This section collects high-level, substantive treatments of luteolin from expert platforms and the narrative research literature.

Four items are listed rather than five. Rhonda Patrick’s only substantive luteolin coverage sits inside a members-only Q&A episode whose content is not readable without a subscription, so it is not listed here. No relevant luteolin content was found on peterattiamd.com or hubermanlab.com; both site searches returned no results. Chris Kresser’s site returns only broad articles on phytochemicals and probiotics in which luteolin appears as a passing example, so none qualifies as a high-level treatment of the topic.

Grokipedia

  • Luteolin

    A structured reference entry covering chemistry, biosynthesis, plant and dietary sources, mast cell stabilization, anticancer and neuroprotective work, and a separate section on clinical evidence and safety.

Examine

No dedicated Examine article on luteolin exists. The site’s search returns only a research-feed study summary of one post-COVID smell trial, which is a feed entry rather than a primary, dedicated page on the compound.

ConsumerLab

  • What are the health benefits of luteolin, and is it safe?

    ConsumerLab’s assessment of luteolin across cancer, heart health, skin aging, cognition, exercise and smell loss, plus product-quality commentary. Its headline judgment is that clinical benefit evidence is generally lacking.

Systematic Reviews

The systematic reviews and meta-analyses below cover the clinical and preclinical evidence base for luteolin.

The risk side of the trade-off is represented only by the drug-interaction review; no systematic review or meta-analysis covers luteolin’s clinical adverse events, so that evidence is drawn from individual trials in the Potential Risks section instead.

Mechanism of Action

Luteolin is a flavone: a flat three-ring plant compound whose adjacent pair of hydroxyl groups drives most of its chemistry.

Its dominant action is signaling, not antioxidant chemistry. Luteolin suppresses NF-κB (nuclear factor kappa B, the master switch that turns inflammatory genes on), lowering tumor necrosis factor and interleukin-6, and activates Nrf2 (nuclear factor erythroid 2-related factor 2, the cell’s own antioxidant-defense switch). It stabilizes mast cells, which release histamine and tryptase, and quiets microglia, the brain’s immune cells. It also activates AMPK (AMP-activated protein kinase, a cellular low-energy sensor) while restraining mTOR (mechanistic target of rapamycin, a growth-signaling hub), and binds CDK6 (cyclin-dependent kinase 6, the enzyme that pushes a cell through division), displacing p16 (a brake protein whose build-up locks cells into senescence).

Two mechanistic accounts compete: the older treats luteolin as a direct free-radical scavenger, the newer holds that blood levels after oral dosing are far too low for scavenging to matter and that benefit comes from mild stress signaling through Nrf2 — predicting a biphasic dose-response in which more is not better.

Luteolin is not selective for one target. Absorption is poor; what is absorbed is rapidly conjugated in gut wall and liver by UDP-glucuronosyltransferases and sulfotransferases (enzymes that attach water-soluble tags for excretion), circulating mainly as glucuronides with elimination half-lives of a few hours. Distribution is wide but tissue levels stay low. In laboratory assays it inhibits CYP1A2 and CYP3A4 (liver enzymes that clear many medications) and carboxylesterase 1 (which switches several medications on).

Historical Context & Evolution

Luteolin was not developed for health at all. It was isolated in the nineteenth century from dyer’s weed (Reseda luteola), a plant grown across Europe to dye cloth yellow, and the compound takes its name from that use. Its first recorded applications were industrial, not medicinal, although herbs that happen to be rich in it — chamomile, perilla, artichoke, thyme — have long histories in traditional medicine for digestive and allergic complaints.

The shift toward health optimization came from three lines of laboratory work. In the 1990s and 2000s, allergy researchers found that flavonoids blocked mediator release from human mast cells, with luteolin among the most potent, which framed it as an anti-allergic and anti-inflammatory agent rather than an antioxidant. In parallel, nutrition groups showed that adding luteolin to the diet of aged mice reduced the inflammatory activation of brain immune cells, cutting the proportion of proinflammatory microglia roughly in half. From 2012 onward, clinicians began testing luteolin-containing formulations in people, first in children with autism spectrum disorder, later in post-viral smell loss and metabolic syndrome.

The framing changed again in 2024, when a mouse lifespan study identified luteolin as the active flavonoid in a plant extract that extended median lifespan and traced the effect to disruption of a specific protein interaction controlling cell senescence. Nothing in this sequence has been overturned, but the interpretation has moved from scavenging chemistry toward targeted signaling, and the human evidence has consistently lagged the laboratory work rather than confirming it.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches this level: no clinical endpoint or validated clinical surrogate has been replicated across more than one trial of luteolin itself, because every randomized trial reporting a benefit has tested a fixed combination product — luteolin with palmitoylethanolamide, with chlorogenic acid, or with mangiferin — while the randomized trials of luteolin alone are either null or still unpublished, leaving no replicated human outcome attributable to luteolin alone.

Medium 🟩 🟩

Recovery of Smell After Viral Olfactory Loss ⚠️ Conflicted

Loss of smell after a respiratory virus is attributed to inflammation in the olfactory bulb, which luteolin plus palmitoylethanolamide is used to damp down alongside olfactory training. Two multicenter randomized trials and a meta-analysis of 441 patients report faster recovery on validated smell testing. A smaller randomized trial found raw scores improved but no advantage on a clinically meaningful threshold, and Cochrane rated the evidence very low certainty. On balance the effect is real but smaller and less certain than the largest trials suggest; luteolin was never given alone.

Magnitude: In the largest randomized trial, 92% of the supplemented group improved versus 42% on olfactory training alone, with mean Sniffin’ Sticks gains of 12.8 versus 3.2 points; the conflicting trial found no between-group difference on clinically meaningful improvement.

Cardiometabolic and Liver Markers in Metabolic Syndrome

A luteolin-plus-chlorogenic-acid extract of artichoke thistle improved glucose, lipid, liver and vascular measures over six months in a double-blind placebo-controlled trial of 100 adults with metabolic syndrome, with the pre-obesity subgroup analyzed separately. The proposed mechanism is AMPK activation with reduced hepatic fat handling. Two caveats matter: this is one trial rather than two, and chlorogenic acid is an active compound in its own right, so the luteolin share of the effect is unresolved. The supplement maker supplied the product.

Magnitude: Over six months versus placebo, relative changes were −0.95% for HbA1c (hemoglobin A1c, average blood glucose over about three months), −21.8% for the fatty liver index, −2.4% for body weight, −39.5% for carotid intima-media thickness (artery wall thickness) and +10.6% for flow-mediated dilation (a measure of blood vessel responsiveness); the two vascular figures are far larger than any six-month intervention has produced elsewhere and are not credible at face value.

Lower All-Cause and Cardiovascular Mortality at Higher Dietary Intake

Two prospective analyses of the same national nutrition and mortality survey found that adults who ate more luteolin-containing foods died less often over follow-up, in type 2 diabetes and in chronic kidney disease. Both report a dose-response gradient, and the diabetes cohort also showed lower C-reactive protein at baseline. These are observational and rest on single 24-hour dietary recalls, so higher luteolin intake plausibly marks a vegetable-rich diet rather than acting on its own; neither study tested a supplement.

Magnitude: In type 2 diabetes, each unit rise in log-transformed daily intake was associated with 7.0% lower all-cause and 22.6% lower cardiac mortality; in chronic kidney disease the corresponding reductions were 27% and 34%. Median intake was roughly 0.3 mg/day in both cohorts.

Low 🟩

Reduction of Post-Viral Cognitive Symptoms

Post-viral mental clouding is attributed to the brain inflammation that drives smell loss. A randomized study in 69 patients found clouding eased over three months, and a placebo-controlled trial in 39 restored cortical inhibition on brain stimulation. Neither isolated luteolin from palmitoylethanolamide, and the first had no untreated arm.

Magnitude: Mental clouding affected 26 of 69 patients (37.7%) and its severity fell between baseline and three months by a statistically significant margin; no between-group effect size is reported, because every arm in that study received the supplement.

Sprint Performance and Muscle Oxygen Extraction

A double-blind crossover trial in twelve physically active men found that luteolin from peanut husk plus mangiferin from mango leaf improved sprint performance, muscle oxygen extraction and brain oxygenation at 48 hours and 15 days. Two authors worked for the manufacturer, and the combination leaves luteolin’s own contribution unresolved.

Magnitude: Mean power output across the sprint tests was 4.0% higher than placebo overall and 5% higher at 48 hours, rising to 15% in the sprint performed under extreme fatigue; peak power improved 22% between 48 hours and 15 days on the supplement, and quadriceps oxygenation index fell about 2–3 percentage points, indicating greater oxygen extraction.

Behavioral and Inflammatory Improvement in Autism Spectrum Disorder ⭕️ Not Central to Health & Longevity

An open-label 26-week trial in 50 children using a liposomal luteolin-quercetin-rutin formulation reported gains in adaptive functioning, and a companion analysis found tumor necrosis factor and interleukin-6 fell most in responders. There was no control group. This bears on luteolin’s anti-neuroinflammatory action, not on longevity.

Magnitude: Adaptive-behavior age-equivalent scores rose about 8 months in communication, 7 in daily living skills and 8 in social functioning over 26 weeks, and problem-behavior subscale scores fell 26.6–34.8%, with no comparator arm.

Anticancer Activity

Luteolin suppresses tumor cell growth and spread in culture and in animals, partly through gene-regulatory microRNA changes catalogued in a systematic review. The only human evidence is an uncontrolled trial in five men with prostate cancer under active surveillance. Concentrations used in vitro exceed achievable blood levels.

Magnitude: On 50 mg daily for six months, two of five men showed a favorable biopsy response, one was stable and two progressed; no controlled trial has measured a cancer outcome.

Speculative 🟨

Clearance of Senescent Cells and Lifespan Extension

A luteolin-standardized plant extract extended median mouse lifespan from 28 to 32.25 months when started at 20 months of age, with luteolin disrupting the p16-CDK6 interaction. No human outcome data exist.

Reduced Brain Inflammation and Cognitive Aging

Dietary luteolin roughly halved the proportion of inflammatory brain immune cells in aged mice. The dedicated luteolin cognition trials in healthy adults have not reported results, so for cognitive aging the basis remains animal work.

Mast Cell Stabilization and Histamine-Driven Symptoms

In cultured human mast cells, luteolin blocked histamine, tryptase and cytokine release more effectively than cromolyn, the only licensed mast cell blocker. The evidence is laboratory-only; no controlled human allergy trial exists.

Protection Against Skin Photoaging

In rat skin and human dermal fibroblasts, luteolin reduced ultraviolet-induced wrinkling and collagen loss. No human trial has measured a skin outcome, so the basis is animal and cell work only.

Delayed Hair Graying

In graying-prone mice, topical and oral luteolin slowed hair graying, suppressing senescent cells in the follicle and restoring the signal that keeps pigment stem cells active. No human data exist.

Strengthening of the Gut Barrier in Colitis

A meta-analysis of 19 animal studies found luteolin restored gut-barrier proteins and lowered inflammatory markers in models of colitis (inflammation of the large bowel). No human trial has tested it.

Reduced Heart Muscle Damage After Blocked Blood Flow

A meta-analysis of animal studies reports luteolin reduced heart muscle damage and improved cardiac pressure measures where coronary blood flow was blocked and then restored. No human cardiac outcome has been measured.

Support for Testosterone Production in Aging Men

In cultured rat testicular cells, luteolin raised testosterone output and the transport protein that limits steroid synthesis. Suppressing estrogen synthesis points the same way. No human hormone measurement after supplementation exists.

Benefit-Modifying Factors

  • COMT and catechol handling: COMT (catechol-O-methyltransferase, the enzyme that attaches methyl groups to compounds with two adjacent hydroxyls) methylates luteolin. Slower-activity variants plausibly raise exposure to unmethylated luteolin, while faster variants clear it sooner; no trial has stratified on genotype.

  • UGT1A1 and sulfotransferase variants: UGT1A1 (a glucuronidation enzyme) and SULT1A1 (a sulfation enzyme) perform most luteolin conjugation. Reduced-function variants raise circulating free luteolin and may amplify both effect and interaction potential.

  • Baseline inflammatory load: Benefit tracks how much inflammation there is to suppress. Adults with elevated high-sensitivity C-reactive protein or metabolic syndrome showed the clearest changes, while the null result in symptom-based illness came in a population without documented inflammation.

  • Baseline smell and metabolic status: In the smell trials, participants with complete loss of smell gained more than those with partial loss. In the metabolic trial, gains were independent of degree of liver fat but largest where glucose and lipid markers started abnormal.

  • Sex and hormonal status: Luteolin suppresses aromatase (the enzyme that makes estrogen). Premenopausal women therefore have a hormonal axis that men do not, which may alter both benefit and tolerability; no trial has reported results split by sex.

  • Pre-existing conditions: Type 2 diabetes, chronic kidney disease and metabolic syndrome are the settings where human signals appear. In healthy adults with normal markers, no trial has demonstrated a measurable benefit on any clinical endpoint.

  • Age: Every clear preclinical benefit — senescent-cell clearance, microglial quieting, lifespan — was produced in aged animals, not young ones. Adults at the older end of the range are the group for whom the mechanistic case is strongest and least tested.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches this level: no adverse event has been documented for luteolin in more than one controlled human trial, since the randomized trials report either no treatment-emergent adverse events at all or none attributable to the supplement, leaving no replicated clinical adverse-event class to grade.

Medium 🟥 🟥

No risk reaches this level either: no single controlled trial and no observational cohort has attributed an adverse outcome to luteolin, since the one systematically collected adverse-event signal comes from an uncontrolled open-label series and the remaining concerns rest on spontaneous reports or laboratory work.

Low 🟥

Transient Irritability and Behavioral Activation

In the 26-week open-label trial of a liposomal luteolin formulation, just over half of participants developed a temporary increase in irritability that resolved within one to eight weeks without stopping treatment. Without a control group, background variation cannot be excluded, and no other human trial has looked for it.

Magnitude: 27 of 50 participants (54%) experienced increased irritability lasting 1–8 weeks; the effect was transient in all cases and no participant discontinued because of it.

Speculative 🟨

Gastrointestinal Upset at Higher Doses

Nausea, bloating and loose stools are reported above 500 mg daily, plausibly from poor solubility and local irritation in the gut. No controlled trial recorded them; the basis is uncontrolled consumer and reference-source reports.

Suppression of Estrogen Production

Luteolin reduced aromatase expression and estrogen output in cultured human ovarian granulosa cells, the main estrogen source in premenopausal women. No human hormone measurements after supplementation have been published.

Reduced Thyroid Iodide Uptake

In a human thyroid cell line, luteolin lowered iodide content and the messenger RNA for the iodide transporter. The effect was transient in culture, and no thyroid function data from supplemented humans exist.

Interference with Drug-Activating and Drug-Clearing Enzymes

A systematic review of natural products ranks luteolin among the strongest laboratory inhibitors of carboxylesterase 1, the liver enzyme that activates clopidogrel and oseltamivir. Clinical confirmation is absent.

Loss of Effect or Reversal at High Doses

Luteolin shows biphasic dose-responses across neuroprotection, wound healing and bone models, meaning doses above the effective window can lose benefit. The dose ceiling in humans is undefined.

Platelet Inhibition and Bleeding Tendency

Luteolin blocked collagen-driven platelet activation and reduced thrombosis in mice, without altering coagulation or bleeding time. The basis is laboratory and animal work; no human bleeding event has been reported.

Allergen Carry-Over from Peanut-Shell Extracts

Several commercial luteolin extracts are made from peanut husk, including the material used in the published exercise trial. No allergic reaction has been reported, but residual protein cannot be excluded without testing.

Risk-Modifying Factors

  • CES1 genotype: Carriers of reduced-function carboxylesterase 1 variants already activate clopidogrel and oseltamivir poorly. Adding an enzyme inhibitor on top plausibly compounds that, making genotype a modifier of interaction risk rather than of luteolin’s own toxicity.

  • UGT1A1 reduced-function variants: Slower glucuronidation raises unconjugated luteolin exposure, which widens the window in which enzyme inhibition and hormonal effects could become clinically visible rather than staying laboratory findings.

  • Baseline thyroid and estrogen markers: Adults already at the low end of free thyroxine or estradiol have less reserve before a small suppressive shift becomes clinically meaningful, whereas adults with normal baselines have substantial headroom.

  • Sex-based differences: Aromatase suppression is relevant mainly to premenopausal women, in whom ovarian estrogen production dominates. Men and postmenopausal women depend far less on that pathway, so the same laboratory finding carries different weight.

  • Pre-existing thyroid, hepatic and bleeding conditions: Treated hypothyroidism, Child-Pugh Class B or C liver impairment, and any anticoagulant or antiplatelet regimen each convert a laboratory-only concern into a plausible clinical one by removing physiological reserve.

  • Age: Older adults carry more medications, so the enzyme-inhibition concerns dominate. They also clear conjugated flavonoids more slowly when kidney function declines, raising exposure at a fixed dose.

Key Interactions & Contraindications

  • Carboxylesterase 1 substrates (clopidogrel, oseltamivir, methylphenidate): Caution. Laboratory inhibition could reduce activation of clopidogrel and oseltamivir or raise methylphenidate levels. Published mitigations are four-hour dose separation, or no overlap during antiplatelet therapy after stenting.

  • CYP3A4 substrates (simvastatin, atorvastatin, midazolam, cyclosporine, tacrolimus): Caution. Inhibition may raise drug levels and, for statins, muscle-injury risk. The usual mitigation is a stable luteolin dose with watchfulness for new muscle pain, rather than medication adjustment.

  • CYP1A2 substrates (theophylline, tizanidine, clozapine, caffeine): Caution. Slowed clearance can amplify effects, most noticeably as jitteriness or sleep disturbance from unchanged caffeine intake. Reducing caffeine is the simplest mitigation.

  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin): Caution. Flavonoids inhibit platelet aggregation, so the theoretical consequence is increased bruising or bleeding. The standard mitigation is discontinuation at least two weeks before planned surgery.

  • Levothyroxine and antithyroid drugs (methimazole, propylthiouracil): Monitor. The laboratory signal is reduced thyroid iodide uptake, which could shift dose requirements. Thyroid-stimulating hormone at three months is the usual monitoring point.

  • Aromatase inhibitors (letrozole, anastrozole, exemestane) and estrogen therapy (estradiol, conjugated estrogens): Caution. Luteolin suppresses aromatase independently, so effects may be additive with inhibitors and opposing to estrogen therapy. The stated mitigation is oncology supervision before combining.

  • Glucose-lowering agents (metformin, glipizide, insulin, semaglutide): Monitor. The metabolic trial showed glucose markers fall, so additive lowering is plausible. Increased home glucose checking during the first month covers it.

  • Antihypertensives (lisinopril, amlodipine, losartan): Monitor. Improved vessel responsiveness in the metabolic trial suggests a mild additive blood-pressure effect. Home blood-pressure readings for four weeks after starting are sufficient.

  • Over-the-counter nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin): Caution. Both affect platelet function, so the consequence is additive bleeding and gastric irritation risk. Sustained daily overlap, rather than occasional use, is the pattern of concern.

  • Over-the-counter antihistamines (cetirizine, loratadine, famotidine): Monitor. Luteolin acts upstream by stabilizing mast cells rather than blocking receptors, so the combination is complementary; the practical consequence is that antihistamine requirements may fall.

  • Flavonoid supplements (quercetin, fisetin, apigenin, epigallocatechin gallate): Caution. All are conjugated by the same enzymes and inhibit the same drug-metabolising pathways, so combining them raises total inhibitory load. Total daily flavonoid intake is the quantity to limit.

  • Blood-glucose-lowering supplements (berberine, chromium, alpha-lipoic acid): Monitor. These lower glucose through separate routes, so the additive consequence is hypoglycemia in adults also on medication. Introductions staggered by four weeks keep the contributions separable.

  • Blood-pressure-lowering supplements (beetroot nitrate, magnesium, fish oil): Monitor. All plausibly add to luteolin’s vascular effect; fish oil also adds to platelet inhibition. One-at-a-time introduction with blood-pressure tracking keeps them distinguishable.

  • Non-heme iron absorption: Monitor. Flavonoids bind iron in the gut and reduce uptake from plant sources. A two-hour gap from iron-rich meals or iron supplements preserves uptake.

  • Senolytic regimens (agents that clear senescent cells: dasatinib with quercetin, fisetin) and chemotherapy (doxorubicin, cisplatin): Caution. Luteolin blunts chemotherapy-induced senescence in animals, desirable for side effects but potentially opposing a treatment’s intent. The stated mitigation is oncology clearance before use during active cancer therapy.

Populations who should avoid Luteolin:

  • Pregnancy and lactation — no human safety data, and the aromatase and thyroid signals concern pathways active in fetal development
  • Known peanut allergy, where the product is peanut-hull derived and not certified protein-free
  • Premenopausal women with estrogen-dependent infertility treatment or ovulation induction under way
  • Adults on aromatase inhibitors for hormone-receptor-positive breast cancer, without oncology supervision
  • Untreated or unstable thyroid disease, including thyroid-stimulating hormone above 4.5 mIU/L or below 0.4 mIU/L
  • Child-Pugh Class B or C hepatic impairment, where conjugation capacity is reduced
  • Within 14 days of planned surgery or a spinal or epidural anesthetic procedure
  • Within 12 months of coronary stent placement while on clopidogrel

Risk Mitigation Strategies

  • Low opening dose of 100 mg daily for two weeks: A low opening dose limits the transient irritability and behavioral activation seen in the open-label trial, which appeared within the first one to eight weeks of exposure.

  • Total daily intake capped at 500 mg: The biphasic dose-response means benefit can be lost above an undefined window, and gastrointestinal upset is reported above that dose. Staying inside the range used in published human trials avoids both.

  • Certified peanut-free botanical source: Selecting Sophora japonica or chamomile-derived material, or peanut-hull extract with documented protein testing, removes the allergen carry-over concern entirely.

  • Four-hour separation from medication doses: Spacing reduces peak overlap with carboxylesterase 1 and CYP substrates, lowering the chance that laboratory enzyme inhibition translates into altered drug levels.

  • Discontinuation 14 days before any surgery: Discontinuation well ahead of a procedure removes the additive platelet-inhibition risk from combined flavonoid and nonsteroidal anti-inflammatory drug use.

  • Thyroid-stimulating hormone recheck at three months: A single follow-up test detects any shift from the reduced iodide uptake seen in thyroid cells, particularly where levothyroxine is already being taken.

  • Estradiol check at three months in premenopausal women: One measurement establishes whether the laboratory aromatase suppression translates into a real hormonal shift before longer-term use continues.

  • Pause during active cancer treatment unless cleared: Pausing avoids the theoretical conflict with chemotherapy regimens that rely on inducing senescence in tumor cells.

Therapeutic Protocol

  • Standard supplement dose: 100–500 mg of purified luteolin daily, taken with food. Most commercial single-ingredient capsules deliver 100 mg; registered trials of single-agent luteolin have used 100–600 mg daily.

  • Liposomal formulation protocol: The autism trial used 100 mg luteolin with 70 mg quercetin and 30 mg rutin in olive kernel oil, dosed at one capsule per 10 kg body weight daily with food.

  • Combination protocol for smell recovery: Co-ultramicronized palmitoylethanolamide 700 mg with luteolin 70 mg, once or twice daily for 90 days, given alongside twice-daily olfactory training.

  • Combination protocol for cardiometabolic markers: A standardized artichoke thistle extract supplying chlorogenic acid plus luteolin, 150 mg once daily for six months, as used in the metabolic syndrome trial.

  • Competing approaches — dietary versus isolated: A food-first approach relies on celery, parsley, thyme, chamomile tea and sweet peppers, and is what the mortality cohorts actually measured. Isolated supplementation delivers far higher doses but has weaker outcome evidence.

  • Competing approaches — plain versus absorption-enhanced: Plain luteolin powder is cheapest but poorly absorbed. Liposomal, phytosome and fenugreek-galactomannan formulations claim multi-fold higher blood levels; only the manufacturers have published the comparisons.

  • Who popularized each approach: Theoharides’ laboratory at Tufts University developed and patented the liposomal luteolin-quercetin formulation, now sold commercially; Di Stadio’s multicenter Italian group established the palmitoylethanolamide-luteolin smell protocol; Rizzo’s group at Palermo ran the artichoke thistle regimen.

  • Best time of day: Morning with breakfast is the usual choice, because the transient activation reported in the open-label trial is easier to tolerate during the day than at night.

  • Half-life and dosing frequency: Human data are limited, but circulating luteolin conjugates peak within about an hour and are largely cleared within several hours, which is why split dosing is used in the combination protocols.

  • Single versus split dosing: Doses above 200 mg are commonly split morning and evening to maintain exposure across the day; the smell-recovery trials tested both once- and twice-daily schedules.

  • Genetic factors in dose choice: Reduced-function UGT1A1 or SULT1A1 variants raise exposure at a given dose, and slow COMT variants prolong it. None of these has been prospectively tested, so genotype informs caution rather than a dose calculation.

  • Sex-based differences: No trial has reported dosing or response split by sex. The aromatase signal gives premenopausal women a reason to use the lower end of the range and to confirm hormone stability.

  • Age-related considerations: Protocols for adults over 65 sit at 100–200 mg daily, reflecting slower conjugate clearance with declining kidney function and a higher background medication count.

  • Baseline biomarkers influencing response: High-sensitivity C-reactive protein, HbA1c and liver enzymes identify the inflammatory and metabolic states in which measurable change has been observed; normal values predict little to measure.

  • Pre-existing conditions influencing response: Metabolic syndrome, type 2 diabetes and post-viral smell loss are the conditions where human response has been documented. Hepatic impairment reduces conjugation and raises exposure at any dose.

Discontinuation & Cycling

  • Lifelong versus short-term: The smell and behavioral protocols are finite courses of 26–90 days. The metabolic and longevity rationales imply indefinite use, which no trial has run beyond six months.

  • No withdrawal effects documented: No published trial reports rebound, discontinuation symptoms or loss of tolerability on stopping. The transient irritability in the open-label trial resolved on continued dosing rather than on withdrawal.

  • Tapering not required: Because no withdrawal syndrome exists and the compound clears within hours, abrupt discontinuation is the norm in every published protocol, including before surgery.

  • Cycling for the biphasic dose-response: A dose-response that rises then falls suggests continuous high-dose exposure may lose effect. Some protocols use five days on and two off, though no trial has compared continuous with cycled dosing.

  • Reassessment point: Where a defined target existed — smell scores, liver and glucose markers — the trials evaluated at 90 days and six months respectively, which are reasonable points to judge whether continuation is warranted.

Sourcing and Quality

  • Botanical source matters for allergens: Luteolin is extracted from Sophora japonica flower buds, peanut husk, chamomile and perilla. Peanut-husk material is common and cheap, and labels rarely disclose it, which leaves the botanical source unverifiable from the label alone.

  • Purity specification: Reputable single-ingredient products state 98% luteolin by high-performance liquid chromatography. Products listing only a plant extract weight without a luteolin percentage make the delivered dose impossible to determine.

  • Third-party testing: Independent verification through NSF International, USP or Informed Choice confirms identity, dose and absence of heavy metals and solvent residues, none of which is guaranteed by dietary supplement regulation.

  • Absorption-enhanced formulations: Liposomal olive-oil, phytosome and fenugreek-galactomannan formats are sold at a premium on bioavailability claims. The supporting pharmacokinetic data are largely manufacturer-held rather than independently published.

  • Named suppliers: Algonot, whose product was developed and patented by the researcher behind the mast-cell account, supplies the liposomal softgel used in the autism trial, and Life Extension the fenugreek-galactomannan format; a compounding pharmacy can prepare a defined dose otherwise.

  • Proprietary blends without per-ingredient amounts: Blends that combine luteolin with quercetin, fisetin or apigenin without per-ingredient amounts prevent dose control and make the combined enzyme-inhibition load impossible to estimate.

  • Luteolin is not lutein: The names differ by two letters but the compounds are unrelated; lutein is a carotenoid for eye health. Mislabelled and miscategorized listings are common in online marketplaces.

Practical Considerations

  • Time to effect: Smell-recovery trials measured change at 30–90 days. The cardiometabolic trial ran six months. Allergic and histamine-related symptom reports describe days to weeks, but rest on uncontrolled observation.

  • Common pitfall — expecting single-agent results: Every controlled trial showing benefit used a fixed combination. Buying plain luteolin and expecting the published smell or metabolic outcomes misreads what was actually tested.

  • Common pitfall — buying on dose alone: Poor absorption means a 500 mg unformulated capsule may deliver less circulating luteolin than a 100 mg absorption-enhanced one. Milligram count alone is not a useful comparison.

  • Common pitfall — taking it without food: Luteolin is poorly water-soluble and absorption improves with dietary fat. Fasted dosing wastes much of the capsule.

  • Regulatory status: In the United States luteolin is sold as a dietary supplement with no premarket approval and no approved indication. In parts of Europe the palmitoylethanolamide-luteolin combination is marketed as a food for special medical purposes.

  • Cost and accessibility: Plain luteolin is inexpensive at roughly 20–60 US cents per day. Formulated and combination products cost several times that. Neither is difficult to obtain without a prescription.

Interaction with Foundational Habits

  • Sleep: Indirect and generally neutral. The only sleep-relevant human signal is the transient activation reported in the open-label trial, which is why morning dosing is standard. Luteolin also slows caffeine clearance through CYP1A2, so unchanged afternoon coffee intake can become a new cause of delayed sleep onset.

  • Nutrition: Direct and potentiating. Dietary fat improves absorption, so dosing with a meal containing oil or nuts is standard. Flavonoids also bind non-heme iron in the gut, so separating luteolin from iron-rich plant meals or iron supplements by two hours protects iron status. Celery, parsley, thyme and chamomile add dietary luteolin.

  • Exercise: Potentiating for sprint work, unresolved for hypertrophy (muscle growth). The only controlled trial found improved sprint performance and muscle oxygen extraction with luteolin plus mangiferin, taken 48 hours to 15 days beforehand. Because luteolin suppresses inflammatory signaling, the theoretical concern that it blunts training adaptation as high-dose antioxidants can has not been tested.

  • Stress management: Indirect. No human study has measured cortisol or stress response on luteolin. The mechanistic link runs through mast cells, which release mediators in response to stress hormones and which luteolin stabilizes in culture. In practice, stress-driven histamine symptoms are the outcome users report tracking, not cortisol itself.

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes whether there is anything measurable to change and captures the two safety axes that laboratory work flags. Inflammatory and metabolic status come first, because those are the states in which human benefit has been observed: high-sensitivity C-reactive protein, HbA1c, fasting insulin and a liver panel. Thyroid-stimulating hormone with free thyroxine, and estradiol in premenopausal women, cover the endocrine signals seen in cell studies. Kidney function guides dose in older adults.

Ongoing monitoring is light because no clinical toxicity has been documented. The practical cadence is a safety recheck of thyroid-stimulating hormone and estradiol at three months, a full repeat of the inflammatory, metabolic and liver panel at six months to match the interval at which the metabolic trial showed change, and annually thereafter while use continues.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
High-sensitivity C-reactive protein < 1.0 mg/L Primary target; identifies whether inflammation exists to suppress Fasting not required. Invalid within two weeks of infection or injury. Conventional labs flag only above 3.0 mg/L
HbA1c 4.8–5.4% Tracks the glucose endpoint that changed in the metabolic trial Reflects roughly three months of average glucose. Conventional cut-off is 5.7%. Pair with fasting insulin
Fasting insulin 2–5 µIU/mL Detects insulin resistance earlier than glucose does Requires a 10-hour fast, drawn in the morning. Most conventional ranges extend to 25 µIU/mL
Alanine aminotransferase < 20 U/L (women), < 25 U/L (men) Liver enzyme; both an outcome and a safety check Fasting not required. Conventional upper limits near 40 U/L miss early fatty liver. Draw with aspartate aminotransferase
Thyroid-stimulating hormone 0.5–2.0 mIU/L Safety check for the reduced iodide uptake seen in thyroid cells Draw in the morning before any levothyroxine dose. Conventional range extends to 4.5 mIU/L
Free thyroxine 1.0–1.5 ng/dL Confirms whether a thyroid-stimulating hormone shift reflects real hormone change Conventional range runs wider, roughly 0.8–1.8 ng/dL. Best paired with thyroid-stimulating hormone on the same draw and at the same time of day
Estradiol (premenopausal women) Cycle-dependent; no single target applies. Track change from the individual’s own baseline drawn on the same cycle day Safety check for the aromatase suppression seen in cell studies Day 3 of the cycle is the conventional standardized draw. Not informative in men or postmenopausal women
Estimated glomerular filtration rate > 90 mL/min/1.73 m² Kidney function; guides dose reduction in older adults Calculated from creatinine. Declines with age; values of 60–89 warrant the lower dose range
Serum tryptase 2–8 ng/mL Baseline mast-cell activity where histamine symptoms are the reason for use Conventional labs flag only above 11.4 ng/mL. Draw at symptom baseline, not during a flare. Only informative if mast-cell involvement is suspected

Qualitative markers are as informative as the panel for most users, and several of the reported effects have no laboratory correlate at all:

  • Smell acuity, tracked against a fixed set of familiar odours rather than by impression
  • Frequency and intensity of histamine-related symptoms such as flushing, itch and nasal congestion
  • Mental clarity and the ability to sustain concentration through a working day
  • Joint and muscle stiffness on waking
  • Sleep onset latency, which detects the interaction with unchanged caffeine intake
  • Exercise recovery and perceived effort during repeated high-intensity efforts

Emerging Research

  • Luteolin and memory in healthy adults: A completed 44-participant study at the University of Basel tested two weeks of luteolin on visual memory (NCT06047899). Results are not yet published. An earlier 40-participant version was terminated by the 2020 COVID-19 lockdown (NCT04468854).

  • Luteolin in schizophrenia: A completed 85-participant trial at the University of Maryland measured global psychopathology, cognition and oxidative stress (NCT05204407). It is the largest single-agent luteolin trial run so far and its outcome will test the neuroinflammation hypothesis directly.

  • Luteolin in athletes: An enrolling 50-participant trial at the University of Jordan measures gene expression in muscle and fat cells alongside physical performance and body composition (NCT07280520), addressing whether the exercise finding survives without mangiferin.

  • Combination therapy in acute stroke: A planned 60-participant trial will test palmitoylethanolamide with luteolin on neurological and functional disability scores after ischemic stroke (NCT06777680), extending the anti-neuroinflammatory claim to an acute clinical endpoint.

  • Postoperative cognitive dysfunction: A planned 100-participant trial in older adults undergoing cardiac surgery will measure cognitive performance after palmitoylethanolamide-luteolin supplementation (NCT07681063), a setting where brain inflammation is well characterized.

  • Evidence that could weaken the case — the null symptom trial: In a placebo-controlled crossover screening trial in Gulf War Illness (Hodgin et al., 2021), luteolin failed to reduce symptom severity at either dose while resveratrol succeeded in the same participants (NCT02909686).

  • Evidence that could weaken the case — certainty assessments: The Cochrane review of post-COVID smell loss (O’Byrne et al., 2022) rated the palmitoylethanolamide-luteolin evidence very low certainty, and a later randomized trial (Gellrich et al., 2024) found no advantage on clinically meaningful improvement.

  • Separating luteolin from its carriers: The decisive open question is whether luteolin alone reproduces any combination result. The artichoke thistle (Castellino et al., 2019), mangiferin (Gelabert-Rebato et al., 2019) and palmitoylethanolamide trials each pair it with a second active compound.

  • Absorption as the rate-limiting step: Formulation work aims to raise circulating luteolin enough to test the mechanisms identified in the mouse lifespan study (Zumerle et al., 2024). The bioavailability data behind current products are held by manufacturers rather than independently published.

Conclusion

Luteolin is a plant compound from everyday vegetables and herbs, concentrated into supplement form. Its action is best understood as quieting inflammatory signaling rather than mopping up free radicals, and laboratory and animal work supporting that role is extensive and consistent.

The human evidence is thinner and carries a structural flaw. Every controlled trial showing benefit paired luteolin with a second active compound, so those results cannot be assigned to luteolin; the only single-agent trial showing benefit was tiny and had no comparison group. Within that limit, the signals are faster recovery of smell and less mental fog after a virus, better glucose, liver and blood vessel measures where metabolic problems exist, and lower death rates among people eating more luteolin-rich food. A trial in a symptom-based illness found nothing, and one review body judged the smell evidence weak.

Safety looks favorable: trials report almost no side effects, and the exceptions are mild — temporary irritability in one uncontrolled study and stomach upset at higher doses. The remaining concerns — estrogen production, thyroid iodine handling and the enzymes that process medications — come from cell studies, never checked in people.

Much of the evidence comes from parties selling luteolin: the supplement maker supplying the metabolic trial extract, the manufacturer employing the exercise trial’s authors, Life Extension, whose absorption data are unpublished, and the researcher whose patented formulation the behavioral trial tested. No insurer or health system has a stake either way, so funding pressure runs through sellers, not payers.

Top - Benefits - Risks - Protocol